WO2004011027A1 - Vaccins multivalents chimeres a conjugue polysaccharidique - Google Patents

Vaccins multivalents chimeres a conjugue polysaccharidique Download PDF

Info

Publication number
WO2004011027A1
WO2004011027A1 PCT/US2003/023736 US0323736W WO2004011027A1 WO 2004011027 A1 WO2004011027 A1 WO 2004011027A1 US 0323736 W US0323736 W US 0323736W WO 2004011027 A1 WO2004011027 A1 WO 2004011027A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsular polysaccharides
type
carrier protein
group
polysaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/023736
Other languages
English (en)
Inventor
Francis Michon
John Kim
Arun Sarkar
Catherine Uitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to AU2003257003A priority Critical patent/AU2003257003A1/en
Publication of WO2004011027A1 publication Critical patent/WO2004011027A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Definitions

  • the present invention provides a multivalent conjugate molecule and methods of using the conjugate to immunize subjects against bacterial infections.
  • a conjugate molecule of the invention comprises multiple bacterial capsular polysaccharides linked to a carrier protein. Accordingly, the conjugate molecule provides immune protection against multiple types of a particular bacteria in a single vaccine.
  • a vaccine comprising such conjugate molecules also provides a protective immunogenic response that is equivalent to that obtained from a multivalent vaccine that is a mixture of single polysaccharides conjugated to carrier protein.
  • conjugate molecules of the invention are used to prevent or attenuate Group B Streptococcus and Meningococcal infections.
  • a trivalent vaccine was previously described in U.S. Patent No.
  • This vaccine included at least two bacterial capsular oligosaccharidic haptens from a gram-negative bacterium and a gram positive bacterium covalently bonded to a carrier protein, thereby producing a trivalent glycoproteinic molecule.
  • the patent discloses that antibodies are produced in response to this vaccine in rabbits and that the rabbit antisera shows bactericidal activity on living strains of Neisseria meningitidis, there is no disclosure that such a vaccine elicits a protective immune response.
  • the degree of protection is equivalent to that obtained using a multivalent vaccine mixture of single polysaccharides linked to a carrier molecule.
  • the present invention provides a vaccine that is not only equivalent in its efficacy to current multivalent vaccine mixtures, but is also more cost-effectively produced.
  • the present invention provides a multivalent conjugate vaccine comprising a carrier protein with at least three different bacterial capsular polysaccharides covalently linked to the carrier protein.
  • the immunogenic molecule often comprises four, five, or six different bacterial capsular polysaccharides covalently linked to the carrier protein.
  • the carrier protein is typically selected from the group consisting of C ⁇ , C ⁇ , tetanus toxoid, diphtheria toxoid, diphtheria toxoid analog CRM197, and a porin protein.
  • the bacterial capsular polysaccharides are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type la, type lb, type II, type III, type V, and type VIII. Frequently, the Group B Streptococcus capsular polysaccharides are type la, type III and type V and the carrier protein is C ⁇ .
  • the bacterial capsular polysaccharides are Neisseria meningitidis capsular polysaccharides selected from the group consisting of A, B, C, W, and Y.
  • the Neisseria meningitidis capsular polysaccharides are B, C, and Y, or C, Y, and W-135; and the carrier protein is a tetanus toxoid or a porin, e.g., recombinant porin B.
  • the immunogenic molecule includes bacterial capsular polysaccharides that are of a size of between 80 and 120 kilodaltons. In particular embodiments, between about 5 and 20% of the sialic acid residues of the bacterial capsular polysaccharides can be covalently linked to the carrier protein. Often, the bacterial capsular polysaccharides are present in equimolar amounts.
  • the invention also provides a method of preparing a multivalent immunogenic molecule, the method comprising covalently linking at least three different bacterial capsular polysaccharides to a carrier protein.
  • covalently linking the bacterial capsular polysaccharides to the carrier protein comprises steps of: (a) oxidizing the polysaccharides; and (b) coupling the oxidized polysaccharides to the carrier protein.
  • the polysaccharides can be coupled to the carrier protein by reductive animation.
  • the polysaccharides are coupled to the carrier protein by a bispacer coupling with a linker.
  • the invention provides methods of preparing a conjugate molecule that comprises bacterial capsular polysaccharides that are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type la, type lb, type II, type III, type V, and type V. Often, the Group B Streptococcus capsular polysaccharides are type la, type III, and type V.
  • the sialic acid residues of the bacterial capsular polysaccharides are oxidized and about 5 and 20% of the sialic acid residues of the bacterial capsular polysaccharides are coupled to protein.
  • the methods of the invention are used to prepare a conjugate molecule wherein the bacterial capsular polysaccharides are Neisseria meningitidis capsular polysaccharide selected from the group consisting of A, B, C, W-135, and Y. Often the polysaccharides are B, C, and Y, or C, Y, and W-135; and the carrier protein is a tetanus toxoid or porin, e.g. , recombinant porin B.
  • the bacterial capsular polysaccharides are Neisseria meningitidis capsular polysaccharide selected from the group consisting of A, B, C, W-135, and Y. Often the polysaccharides are B, C, and Y, or C, Y, and W-135; and the carrier protein is a tetanus toxoid or porin, e.g. , recombinant porin B.
  • the invention provides a method of preventing or attenuating an infection in a mammal, the method comprising administering to the mammal a multivalent immunogenic molecule comprising a carrier protein with at least three different bacterial capsular polysaccharides covalently linked to the carrier protein, wherein the multivalent immunogenic molecule is administered in an amount sufficient to elicit protective antibodies against the bacterial capsular polysaccharides.
  • the multivalent immunogenic molecule is administered to prevent or attenuate an infection caused by Group B Streptococcus and the bacterial capsular polysaccharides of the immunogenic molecule are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type la, type lb, type II, type III, type V, and type VIII.
  • the carrier protein is typically selected from the group consisting of C , C ⁇ , tetanus toxoid, and diphtheria toxoid.
  • the polysaccharides are type la, type III, and type V and the carrier protein is C ⁇ .
  • the multivalent immunogenic molecule is administered to prevent or attenuate an infection caused by Neisseria meningitidis and the bacterial capsular polysaccharides of the immunogenic molecule are different Neisseria meningitidis capsular polysaccharides selected from the group consisting of A, B, C, W-135, and Y.
  • the Neisseria meningitidis capsular polysaccharides are B, C, and Y, or C, Y, and W-135; and the carrier protein is a tetanus toxoid or a porin such as recombinant porin B.
  • the invention also provides a method of preventing or attenuating an infection caused by a Group B Streptococcus in a mammal, the method comprising administering a multivalent immunogenic molecule comprising a carrier protein with at least three different bacterial capsular polysaccharides covalently linked to the carrier protein, wherein the bacterial capsular polysaccharides are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type la, type lb, type II, type III, type V, and type VIII; and, wherein the immunogenic molecule is administered to a pregnant female in an amount sufficient to confer immunity to the infection in utero to an offspring of the female.
  • the carrier protein is selected from the group consisting of C ⁇ , C ⁇ , tetanus toxoid, and diphtheria toxoid.
  • the Group B Streptococcus capsular polysaccharides are type la, type III and type V and the carrier protein is C ⁇ .
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a multivalent immunogenic molecule comprising a carrier protein with at least three different bacterial capsular polysaccharides covalently linked to the carrier protein and a pharmacological acceptable carrier, wherein the multivalent immunogenic molecule is in an amount sufficient to elicit protective antibodies against the three different bacterial capsular polysaccharides.
  • the carrier protein is frequently selected from the group consisting of C ⁇ , C ⁇ , tetanus toxoid, and diphtheria toxoid. Are there other carrier proteins.
  • the bacterial capsular polysaccharides are different Group B Streptococcus capsular polysaccharides selected from the group consisting of type la, type lb, type II, type III, type V, and type VIII. Often, the Group B Streptococcus capsular polysaccharides are type la, type III and type V.
  • Figure 1 provides a schematic showing the preparation of a
  • Figure 2 shows the structures of the repeating units of the Group B Streptococcus polysaccharides la, lb, II, III and V.
  • Figure 3 shows Molar Mass determinations by SEC-MALLS for GBS polysaccharides prior to being conjugated.
  • Figure 4 shows the structure of an oxidized GBS polysaccharide having an aldehyde group in its terminal sialic acid.
  • Figure 5 provides a schematic showing a conjugation reaction carried out by reductive amination.
  • Figure 6 provides a table showing all expected methylated monosaccharides from methylation analysis in the types la, lb, II, III, and V capsular polysaccharides.
  • Figure 7 shows a chromatographic trace (GC) of PMAA (partially methylated alditol acetates) derivatives from a GBS mulitvalent chimeric (la, III, an V) conjugate.
  • PMAA partially methylated alditol acetates
  • Figure 8 shows results of an ELISA competition experiment in vitro demonstrating that the type la polysaccharide in the chimeric conjugate competes for binding with a type la polysaccharide conjugate monovalent counterpart.
  • Figure 9 shows results of an ELISA competition experiment in viti'o demonstrating that the type III polysaccharide in the chimeric conjugate competes for binding with a type III polysaccharide conjugate monovalent counterpart.
  • Figure 10 shows results of an ELISA competition experiment in vitro demonstrating that the type V polysaccharide in the chimeric conjugate competes for binding with a type V polysaccharide conjugate monovalent counterpart.
  • Figure 11 shows that a chimeric Ia III/V GBS vaccine conjugate elicits a protective immune response in the neonatal mouse model similar to that of a combination vaccine composed of a mixture of the individual serotype Ia/III/V polysaccharide conjugates.
  • Figure 12 shows a chromatogram (GC) of trimethylsilyl methyl glycoside derivatives obtained from a meningococcal C/Y/W-135 chimeric conjugate.
  • Figure 13 shows that a meningococcal chimeric vaccine conjugate elicits a protective immune response similar to that elicited by a combination vaccine composed of a mixture of the individual serogroup CWY polysaccharide conjugates.
  • a "bacterial capsular polysaccharide” is a polysaccharide that is the predominant carbohydrate present in a capsule of a bacteria.
  • the term includes functional derivatives or variants of the polysaccharides.
  • a Group B Streptococcus polysaccharide is any group B-specific or type-specific polysaccharide.
  • carrier refers to a polypeptide moiety to which the polysaccharide antigens are covalently linked.
  • a carrier protein is often immunogenic and therefore also contributes to the "valency" of the vaccine. Linkage to the carrier protein typically increases the antigenicity of the conjugated carbohydrate molecules.
  • the carrier protein may be from the same target organism as the polysaccharides linked to it or may be from a different organism.
  • protein are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one of more amino acid residue is an artificial chemical analog of a corresponding naturally occurring amino acid as well as to naturally occurring amino acid polymers. The term also includes variants on the traditional peptide linkage joining the amino acids making up the polypeptide. [36] “Conservatively modified variants”, “analogs”, or “functional derivative” refer to an amino acid sequence that includes a modification to the sequence compared to the native or naturally sequence, but retains the same biological function, i.e., the ability to act as a carrier protein that is at least equal to that of the native molecule.
  • the following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6)
  • a "multivalent" molecule or vaccine comprises more than one antigenic epitope.
  • multivalent vaccines of the invention often comprise at least three different bacterial polysaccharides conjugated to a single carrier protein. Such a vaccine therefore comprises four antigenic determinants and is a tetravalent vaccine.
  • chimeric refers to a multivalent vaccine in which at least two different polysaccharides are conjugated to the carrier.
  • "Linked” “joined” or “conjugated” refer to covalent linkage of a carbohydrate to the carrier protein. The covalent linkage can be direct or indirect, e.g., linked through a spacer molecule.
  • the term “purified” means substantially free of the various protein, lipid, and carbohydrate components that naturally occur with the polysaccharide. In particular, purified oligosaccharide, or bacterial capsule polysaccharide, is substantially free of intact polysaccharide capsule, or fragments of it having a molecular weight above 100,000.
  • purified polysaccharide does not exclude synthetic oligosaccharide preparations retaining artifacts of their synthesis; nor does the term exclude preparations that include some impurities, so long as the preparation exhibits reproducible polysaccharide characterization data, for example molecular weight, sugar residue content, sugar linkages, cl romatographic response, and immunogenic behavior.
  • composition that is tolerated by a recipient patient.
  • pharmaceutically acceptable refers to a composition that is tolerated by a recipient patient.
  • a “pharmaceutical excipient” is administered as a component of a vaccine in conjunction with the immunogenic multivalent molecule. Excipients comprise a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservative, and the like.
  • a "protective immune response” or “therapeutic immune response” refers to a B lymphocyte and/or T lymphocyte response to a conjugate molecule of the invention that prevents or at least partially arrests or attenuates a bacterial infection and/or disease symptoms or progression caused by the infection.
  • the immune response can include an antibody response that has been facilitated by the stimulation of helper T cells.
  • a "patient” or “recipient” is an animal that is a target of vaccination with a conjugate molecule of the invention. The patient is most often a human.
  • Vaccines to immunize against bacterial polysaccharides are well known in the art. These vaccines comprise purified bacterial capsular polysaccharides that are typically linked to a carrier. Such vaccines for Group B Streptococcus are disclosed, e.g., in U.S. Patent Nos. 5,993,825; 5968521; 5,908,629; 5,858,362; 5,847,081; 5,843,461; 5,843,444; 5,8200,850; and 5,705,580). Similar vaccines have also been developed for Neisseria meningitidis (see, e.g. U.S. Patent Nos.
  • the present invention provides multivalent vaccine conjugate molecules that include multiple bacterial capsular polysaccharides linked to a single carrier protein.
  • the invention also provides methods of producing such vaccines and methods of using the vaccines to obtain protective immunization.
  • Multivalent vaccines that are mixtures of single polysaccharides conjugated to a carrier molecule are well-known in the art and used to confer immune protection against multiple bacterial types.
  • the present invention provides a multivalent vaccine conjugate molecule that is as effective as a multivalent vaccine mixture in eliciting a protective immune response.
  • the invention provides vaccines and methods of using the vaccines to provide protective immunity against Group B Streptococcus and Neisseria meningitidis.
  • Bacterial capsular polysaccharides are the carbohydrate moieties that comprise the capsule coating bacteria. These have been extensively evaluated for many different bacteria.
  • the vaccines of the invention comprise purified polysaccharides or polysaccharide derivatives that are modified versions of the polysaccharide that typically exhibit increased immunogenicity relative to the unmodified version of the polysaccharide.
  • bacterial capsular polysaccharides can be used in the methods of the invention. These include polysaccharides from bacteria including, but not limited to gram-positive bacteria such as Streptococci, Staphylococci, Enterococci, Bacillus, Corynebacterium, Listeria, Erysipelothrix, and Clostridium.
  • gram-positive bacteria such as Streptococci, Staphylococci, Enterococci, Bacillus, Corynebacterium, Listeria, Erysipelothrix, and Clostridium.
  • Non-limiting examples of gram-negative bacteria for use with this invention include Haemophilus influenzae, Neisseria meningitidis and Escherichia coli.
  • the polysaccharides are typically isolated from Group B Streptococcus types, as further described below; Neisseria meningitidis polysaccharides, further described below; Hemophilus influenzae polysaccharides, such as serotype b, Streptococcus pneumonia polysaccharides including types 6A, 6B, 10A, 11 A, 18C, 19A, 19f, 20, 22F, and 23F, and various Escherichia coli polysaccharides including Kl, K2, K12, K13, K92, and K100 polysaccharides.
  • the polysaccharide capsule of Group B Streptococcus is well characterized and has been shown to play a role in both virulence and immunity (Kasper, et al, Infect. Dis. 153:407-415, 1986).
  • Group B streptococci can be further classified into several different types based on the bacteria's capsular polysaccharide. Types la, lb, II, III, IV, V, VI, VII, and VIII account for most of the pathogenicity due to group B infection, with group B streptococci types la, lb, II, III, and V representing over 90% of all reported cases.
  • the structure of each of these various type polysaccharides has been characterized (19-22, 44).
  • the recognized Group B Streptococcus types and subtypes have chemically related but antigenically distinct capsular polysaccharides having a repeating structure composed of galactose, glucose, N-acetyl glucosamine, and N-acetyl-neuraminic (sialic) acid.
  • Neisseria meningitidis is a causative agent of bacterial meningitis and sepsis. Meningococci are divided into serological groups based on the immunological characteristics of capsular and cell wall antigens. Currently recognized serogroups include A, B, C, D, W-135, X, Y, Z and 29E. The polysaccharides responsible for the serogroup specificity have been purified from several of these groups, including A, B, C, D, W-135 and Y.
  • the polysaccharides that are incorporated into a conjugate multivalent molecule of the invention include polysaccharide derivatives, i.e., modified polysaccharides, as well as the native forms purified from the bacteria. Such modified polysaccharides often exhibit enhanced antigenicity relative to the native purified polysaccharide.
  • modified polysaccharides often exhibit enhanced antigenicity relative to the native purified polysaccharide.
  • modifications of bacterial capsular polysaccharides are well known in the art and include such modifications as N- propionylation and de-O-acetylation.
  • Neisseria meningitidis in its native form exhibits little antigenicity. Modified forms are therefore often used in vaccines to circumvent the poor immunogenicity of the native carbohydrate. Modifications of type B polysaccharide include C 3 -C 8 N-acyl- substituted polysaccharide derivatives, which have been described e.g., in EP Publication No. 504,202 B, to Jennings et al. Similarly, U.S. Pat. No. 4,727,136 to Jennings et al. describes an N-propionylated polysaccharide type B in which N- propionyl groups are substituted for N-acetyl groups. The de-O-acetylation of group C meningococcal polysaccharides to enhance immunogenicity is described in U.S. Patent No. 5,425,946. Methods for producing these derivatives are disclosed in the cited references.
  • Bacterial capsular polysaccharides can be purified in a variety of ways. Large-scale production of capsular polysaccharides and capsular polysaccharide conjugate vaccines, requires adequate supplies of purified capsular polysaccharides. Purification techniques that are particular useful in the invention yield polysaccharides that are uniform in size and reproducibly exhibit the same immunogenic properties. Methods for isolating capsular polysaccharides from bacterial cells include treatment of cells with the enzyme mutanolysin, which cleaves the bacterial cell wall to free the cell wall components. This procedure involves treating cell lysates with additional enzymes to remove proteins and nucleic acids and purification by differential precipitation and chromatography.
  • U.S. Patent No. 6,248,570 describes a base-extraction method to obtain large quantities of capsular polysaccharides from cultures of bacteria. Following treatment with base, the polysaccharides are subjected to ultrafiltration to remove proteins and nucleic acids, thereby providing a polysaccharide preparation of relatively uniform molecular weight and free of contaminants. The polysaccharides can then be prepared for conjugation to the carrier protein, via a direct or indirect linkage, as further described below.
  • Carrier proteins [56] Any number of carrier proteins can be used in the invention.
  • the carrier when introduced into the recipient animal, e.g., a human, typically increases the immunogenicity of the linked polysaccharides but may also elicit antibodies that are capable of reacting to a protein expressed by the bacteria from which is derived. Conjugation of the polysaccharides to the carrier usually converts the immune response to the polysaccharide, most often T-cell independent, to one that is T-cell dependent.
  • the carrier protein can have the native amino acid sequence or can be a functional derivative or conservative modification of the native amino acid sequence.
  • the term functional derivative includes fragments of a native protein, or variants of a native sequence, e.g., proteins that have changes in amino acid sequence, but retain the ability to elicit an immunogenic, virulence or antigenic property as exhibited by the native protein).
  • Various carrier proteins and analogs of the carrier proteins are well known in the art. These include, but are not limited to, carriers disclosed in U.S Patent No. 5,425,946, e.g., tetanus toxoid; non-toxic diphtheria toxoid and analogs, e.g., CRM197; the C protein of group B Streptococcus; and the outer membrane protein (porin protein) of Neisseria meningitidis. Suitable proteins can readily be identified by those of skill in the art.
  • CRM197 non- toxic diphtheria toxin analog
  • the CRM197 protein is a nontoxic form of diphtheria toxin, which is produced by C. diphtheriae infected by the nontoxigenic phage ⁇ l97 t0 ⁇ - created by nitrosoguanidine mutagenesis of the toxigenic Corynephage ⁇ . (see, e.g., Uchida. et al, Nature New Biology 233:8-11, 1971).
  • This carrier protein and other diphtheria toxin variants are widely used in the art and can be used for the preparation of many protein-polysaccharide conjugates (see, e.g, U.S. Patent Nos. 4,761,283 and 5,614,382).
  • a C ⁇ or C ⁇ carrier is often used.
  • the C protein(s) are a group of a cell surface associated protein antigens of Group B Streptococcus (see, e.g., Wilkinson et ah, J. Bacteriol. 97:629-634 (1969), Wilkinson, H. W, et al, Infec. andlmmun. 4:596-604 (1971)).
  • Two antigenically distinct populations of C proteins have been described, those that are sensitive to degradation by pepsin but not by trypsin, C ⁇ and. those that are sensitive to degradation by both pepsin and trypsin, C ⁇ .
  • Method of producing C ⁇ and C ⁇ and analogs of the proteins are described, e.g., in U.S. Patent 5,908,629.
  • Porins may also be used as carriers.
  • the meningococcal porins are divided into three major classifications, Class 1, 2, and 3 (Frasch et al, Rev. Infect. Dis. 7:504-510, 1985).
  • Each meningococcus contains one of the alleles for either a Class 2 porin gene or a Class 3 porin gene but not both (see, e.g., Feavers et al, Infect. Immun. 60:3620-3629, 1992; and Murakani et al, Infect. Immun. 57:2318- 2323, 1989).
  • Methods of preparing porin proteins and analogs are known in the art. In particular, methods of expressing the outer membrane protein meningococcal group B porin proteins, por B, are described in U.S. Patent Nos. 6,013,267 and 5,439,808 to Blake et al.
  • Any method of covalently linkage may be employed to conjugate the purified polysaccharide components to the carrier, including both direct and indirect methods.
  • Such methods are well known in the art (see, e.g. , Jacob, et al. , Eur. J. Immunol. 16:1057-1062, 1986; Parker et al, In: Modern Approaches to Vaccines, Chanock, et al, eds, pp. 133-138, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1983; Zurawski et al, J. Immunol. 121:122-139, 1978; Klipsxein et al. , Infect. Immun. 37:550-557, 1982; Bessler et al. , Immunobiol.
  • the conjugates are produced by reductive animation, i.e., reacting the reducing end groups of the bacterial capsular polysaccharides to primary amino groups of the carrier protein by reductive amination.
  • the reducing groups can be formed by selective hydrolysis or specific oxidative cleavage, or a combination of both.
  • the polysaccharide is conjugated to the carrier protein by the method of Jennings et al, U.S. Pat. No. 4,356,170, which involves controlled oxidation of the polysaccharide with periodate followed by reductive amination with the carrier protein.
  • a Group B Streptococcus capsular polysaccharide is purified, N-acetylated and subjected to periodate oxidation sufficient to introduce an aldehyde group into two or more terminal sialic acid residues linked to the backbone of the polysaccharide.
  • the oxidized polysaccharide is conjugated to the carrier through reductive amination to generate a secondary amine bond between the capsular polysaccharide and the protein.
  • conjugate molecules for linkage to the protein carrier via reductive amination
  • equimolar amounts of the purified polysaccharides are mixed and oxidized to the extent that 5%-20% of the terminal sialic acid residues are oxidized.
  • the mixture is then conjugated to the carrier, e.g. , using NaBH 3 CN and the conjugate molecule purified.
  • the conjugate vaccines of the invention are not limited to those produced via reductive amination or other methods of direct linkage of the polysaccharides to the protein moiety.
  • the vaccines may also be produced by conjugating the polysaccharides indirectly to the carrier via any linking method known to those skill in the art such as spacer molecule.
  • spacer molecule such as spacer molecule.
  • an adipic dihydrazide spacer as described by Schneerson, et al, J. Exp. Med., 1952:361-476, 1980, and in U.S. Patent No. 4,644,059 can be employed to link the polysaccharide to the carrier.
  • Other examples include the use of binary spacers as described by Marburg et al, J. Am. Chem.
  • the binary spacers are bigeneric spacers containing a thioether group and primary amine which form hydrolytically-labile covalent bonds with the polysaccharide and carrier protein.
  • the conjugate molecules of the invention are typically administered as a pharmaceutical composition in a pharmacologically acceptable carrier.
  • the compositions may comprise standard carriers, buffers or preservatives known to those in the art which are suitable for vaccines including, but not limited to, any suitable pharmaceutically acceptable carrier, such as physiological saline or other injectable liquids.
  • Additives customary in vaccines may also be present, for example stabilizers such as lactose or sorbitol and adjuvants to enhance the immunogenic response.
  • Adjuvants are substances that can be used to specifically augment a specific immune response. The adjuvant and the composition are typically mixed prior to presentation to the immune system or presented separately, but into the same site of the individual being immunized.
  • Adjuvants can be categorized into several groups based on their compositions. These groups include oil adjuvants, e.g., Freund's Complete and Incomplete adjuvants; mineral salts, for example, Al(OH) 3 , AlNa(SO 4 ) , AlNH 4 (SO 4 ), silica, kaolin, and carbon; polynucleotides such as poly Ic, poly AU acids, and CpG; and certain natural substances such as wax D from Mycobacterium tuberculosis as well as substances found in Corynebacterium parvum or Bordetella Pertussis, and member of the genus Brucella. Among those substances often used as adjuvants are the saponins, for example Quil A (Superfos A/S,
  • the vaccines of the invention can be administered by a variety of routes including parenterally by injection, rapid infusion, intravenously, subcutaneously, intradermally, or intramuscularly. Administration can also be by nasopharyngeal absorption (intransopharangeally), dermoabsorption, or orally.
  • Compositions for parenteral adminsitration include sterile adqueous or non-adqueous solutions, suspensions, and emulstions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption.
  • Liquid dosage forms for oral administration can generally comprise a liposome solution containing the liquid dosage form.
  • Suitable forms for suspending liposome include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water.
  • inert diluents such as purified water.
  • such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, or sweetening, flavoring, or perfuming agents.
  • the vaccines can be administered in a number of different regimens as is apparent to one of skill in the art.
  • the vaccines can be administered as either single or multiple dosages of an effective amount.
  • the vaccines of the invention are administered to a patient in an amount sufficient to elicit a protective immune response and to prevent or attenuate a bacterial infection.
  • An amount adequate to accomplish this is defined as "therapeutically effective dose.” Amounts effective for this use will depend on, e.g. , the particular composition administered, the manner of administration, and factors such as the size, weight or age of the individual receiving the vaccine.
  • effective amounts of the compositions range from 0.01-1,000 ⁇ g/ml per dose, often 0.1-500 ⁇ g/ml per dose and frequently 10-300 ⁇ g/ml perdose.
  • the timing of the dosages can vary.
  • the dosages are administered one to two months apart.
  • the antibody response in an individual can be monitored by assaying for antibody titer or bactericidal activity and boosted if necessary to enhance the response.
  • a single dose for an infant is about 10 ⁇ g of conjugate vaccine per dose or about 0.5 ⁇ g-20 pg/kilogram.
  • Adults generally receive a dose of about 0.5 ⁇ g-20 ⁇ g/kilogram of the conjugate vaccine.
  • the vaccines can be administered maternally to confer neonatal immunity.
  • the vaccine comprising the conjugate molecules of the invention are administered in an immunogenic amount to a female human so as to produce antibodies capable of passing into a fetus in an amount sufficient to produce protection against infection in the neonate at birth.
  • antibodies directed against the vaccine conjugates of this invention may be used as a pharmaceutical preparation in a therapeutic or prophylactic application in order to confer passive immunity from a host individual to another individual (i.e., to augment an individual's immune response against gram-negative or gram-positive bacteria or to provide a response in immuno-compromised or immuno-depleted individuals such as AIDS patients).
  • antibodies directed against the conjugate molecule are generated in an immunocompetent host, harvested from the host, and transfused into a recipient individual.
  • a human donor may be used to generate antibodies reactive against a conjugate of the invention.
  • the antibodies may then be administered in therapeutically or prophylactically effective amounts to a human recipient in need of treatment, thereby conferring resistance in the recipient against bacteria which are bound by antibodies elicited by the polysaccharide component.
  • each polysaccharide in a multivalent GBS conjugate vaccine can be quantified by using chemical derivatization and gas chromatography to distinguish particular linkages that are unique for a specific polysaccharide.
  • Figure 6 shows a table of all linked monosaccharides in the types la, lb, II, III, and V capsular polysaccharides. The asterisk indicates a diagnostic linkage.
  • the neutral hexoses (Glc and Gal) can be analyzed by sequential methylation, hydrolysis, reduction, and acetylation to form partially methylated alditol acetate (PMAA--) derivatives.
  • the amino sugar (GlcNAc) and sialic acid (NANA) can be derivatized by methylation, methanolysis, re-N-acetylation, and trimethylsilylation to form methylated trimethylsilyl (M/TMS) derivatives.
  • FIG. 7 shows a chromatogram of PMAA derivatives from a GBS multivalent chimeric (la, III, and V) conjugate.
  • the PMAAs were chromatographed on a 30-meter RTX-1 capillary column using an HP6890 gas chromatograph with flame ionization detection.
  • Five PMAAs, resulting from the three polysaccharides, were clearly resolved with the expected ratio of l(t-Glc):3(4-Glc):4(3-Gal):2(3,4- Gal):l(4,6-Glc).
  • a fingerprint of PMAAs for each polysaccharide with relative integration of peak areas can be determined to quantify each polysaccharide in the multivalent conjugate.
  • Table 1 shows the quantitative data analysis for the GBS Ia/III/V multivalent conjugate.
  • the relative peak areas from the GBS V fingerprint in Figure 7 are normalized relative to 4,6-Glc, a diagnostic linkage for GBS V, in the multivalent conjugate.
  • the GBS V peak areas are then subtracted from the total peak areas of the multivalent conjugate.
  • the relative peak areas of GBS la and GBS III are sequentially subtracted, normalized against 3,4-Gal and 3- Gal, respectively.
  • the percentage of each polysaccharide in the multivalent conjugate is calculated based on 4-Glc, and a relative value for each polysaccharide is determined.
  • the multivalent conjugate was tested for the ability to elicit a protective immune response.
  • the efficacy of the tetravalent chimeric conjugate prepared as described herein was evaluated in comparison to a tetravalent vaccine mixture comprising , a Ia/Ib/III/V combination vaccine, i.e., a mixture of monovalent conjugates.
  • Animals (CD1 female mice) were inoculated with the chimeric vaccine or the combination tetravalent vaccine mix. Each animal received 1 ⁇ g of each of the conjugated type-polysaccharide, at days 0 and 21. Vaccines were adsorbed on Aluminum hydroxide (Superfos, Denmark). Mice were inpregnated at day 21.
  • Meningococcal polysaccharides from serogroups C, Y, and W- 135 were prepared using the methodology employed from the preparation of the GB S polysaccharides.
  • the Meningococcal polysaccharides contain monosaccharide residues that are unique for each polysaccharide: the serogroup C polysaccharide is a homopolymer of sialic acid residues, the serogroup Y polysaccharide is made up of repeating disaccharide units of glucose and sialic acid, and the W-135 polysaccharide is made up of galactose and sialic acid repeating structures.
  • GC gas chromatography
  • Figure 12 shows a chromatogram of trimethylsilyl (tms) methyl glycosides from a Mening C/Y/W-135 chimeric conjugate.
  • the sample was methanolyzed, derivatized and chromatographed on a 30-meter RTX-1 capillary column using a HP6890 gas chromatograph with flame ionization detection (GC- FID).
  • GC- FID flame ionization detection
  • Three monosaccharides galactose, glucose and sialic acid
  • Table 2 shows the relative polysaccharide (PS) ratios for the

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une molécule de vaccins à conjugué multivalent chimère et des procédés d'utilisation du conjugué pour immuniser des sujets contre des infections bactériennes. Une molécule conjuguée de l'invention comprend des polysaccharides capsulaires multiples bactériens liés à une protéine porteuse. Par conséquent, la molécule conjuguée confère une protection immune contre des types multiples de bactéries dans un seul vaccin. En particulier, les molécules conjuguées de l'invention sont utilisées pour prévenir ou atténuer des affections à Streptococcus et méningococciques du groupe B.
PCT/US2003/023736 2002-07-30 2003-07-30 Vaccins multivalents chimeres a conjugue polysaccharidique Ceased WO2004011027A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003257003A AU2003257003A1 (en) 2002-07-30 2003-07-30 Chimeric multivalent polysaccharide conjugate vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39994902P 2002-07-30 2002-07-30
US60/399,949 2002-07-30

Publications (1)

Publication Number Publication Date
WO2004011027A1 true WO2004011027A1 (fr) 2004-02-05

Family

ID=31188646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023736 Ceased WO2004011027A1 (fr) 2002-07-30 2003-07-30 Vaccins multivalents chimeres a conjugue polysaccharidique

Country Status (3)

Country Link
US (2) US20040096461A1 (fr)
AU (1) AU2003257003A1 (fr)
WO (1) WO2004011027A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110381A1 (fr) 2005-04-08 2006-10-19 Wyeth Composition conjuguee polysaccharide-proteine pneumococcique polyvalente
JP2008518953A (ja) * 2004-11-01 2008-06-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 連鎖球菌修飾多糖類およびそれらの使用法
WO2006082530A3 (fr) * 2005-02-01 2008-07-03 Novartis Vaccines & Diagnostic Conjugaison de saccharides capsulaires streptococciques
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2010049806A1 (fr) 2008-10-27 2010-05-06 Novartis Ag Procédé de purification
EP2270056A2 (fr) 2005-02-01 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Purification du polysaccharide capsulaire de streptococcus
WO2011051917A1 (fr) 2009-10-30 2011-05-05 Novartis Ag Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7972608B2 (en) * 2003-06-23 2011-07-05 Baxter International Inc. Carrier proteins for vaccines
WO2012035519A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Compositions immunogènes
WO2013009564A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Procédé de ligature de la tyrosine
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
WO2013068949A1 (fr) 2011-11-07 2013-05-16 Novartis Ag Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
US8529908B2 (en) 2005-01-14 2013-09-10 Novartis Ag Meningococcal conjugate vaccination
WO2013174832A1 (fr) 2012-05-22 2013-11-28 Novartis Ag Conjugué de sérogroupe x de méningocoque
WO2014053607A1 (fr) 2012-10-03 2014-04-10 Novartis Ag Compositions immunogènes
US8895724B2 (en) 2005-04-08 2014-11-25 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104174019A (zh) * 2014-09-23 2014-12-03 成都康华生物制品有限公司 四价脑膜炎球菌多糖载体蛋白结合疫苗
EP2891498A1 (fr) 2007-12-20 2015-07-08 Novartis AG Procédés de fermentation pour cultiver des streptocoques et procédés de purification pour obtenir des CPS à partir de ceux-ci
US9107872B2 (en) 2005-12-22 2015-08-18 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
US20160324950A1 (en) * 2015-05-04 2016-11-10 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2017001586A1 (fr) * 2015-07-01 2017-01-05 Glaxosmithkline Biologicals S.A. Compositions immunogènes
WO2018087635A1 (fr) * 2016-11-09 2018-05-17 Pfizer Inc. Protéine et polysaccharide immunogènes conjugués comprenant un polysaccharide dérivé du streptococcus gbs
WO2018104889A1 (fr) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Procédé de purification pour polysaccharide capsulaire
WO2022043855A1 (fr) * 2020-08-26 2022-03-03 Pfizer Inc. Conjugués polysaccharide-protéine de streptococcus du groupe b, procédés de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations
RU2791468C2 (ru) * 2016-11-09 2023-03-09 Пфайзер Инк. Иммуногенные полисахарид-белковые коньюгаты, содержащие полисахарид, полученный из стрептококка группы b (gbs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
SK288007B6 (sk) * 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
KR101711903B1 (ko) 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
ES2883343T3 (es) * 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
WO2016168815A1 (fr) * 2015-04-16 2016-10-20 Iventprise LLC Compositions de vaccin immunogène à base de bordetella pertussis
CN118236477B (zh) 2016-09-02 2025-04-25 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) * 2017-06-10 2024-07-19 创赏公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711779A (en) * 1985-07-05 1987-12-08 Sclavo S.P.A. Glycoproteinic conjugates having trivalent immunogenic activity
WO2000010599A2 (fr) * 1998-08-19 2000-03-02 North American Vaccine, Inc. Conjugue de proteine-polysaccharide immunogene a liaison beta-propionamido, utile comme vaccin etabli au moyen d'un polysaccharide n-acryloyle
US6372222B1 (en) * 1995-06-07 2002-04-16 Baxter International Inc. Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
US5425946A (en) * 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
IL107103A (en) * 1992-09-24 2001-03-19 Brigham & Womens Hospital Multivalent vaccine based on conjugated molecule comprising a capsular polysaccharide linked to a protein and a method for the preparation thereof
ES2231770T3 (es) * 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
KR100376361B1 (ko) * 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
IT1282651B1 (it) * 1996-02-19 1998-03-31 Atohaas Holding Cv Processo per la preparazione di perle di polimeri a base acrilica
CA2284606A1 (fr) * 1997-03-26 1998-10-01 Brigham And Women's Hospital, Inc. Procede de production de fragments de saccharide
CA2316975C (fr) * 1997-12-23 2009-03-24 North American Vaccine, Inc. Procedures permettant d'extraire et d'isoler des polysaccharides capsulaires bacteriens destines a etre utilises seuls, en tant que vaccins ou, lies a des proteines, en tant que vaccins conjugues
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
NZ622900A (en) * 2001-01-23 2015-11-27 Sanofi Pasteur Inc Multivalent meningococcal polysaccharide-protein conjugate vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711779A (en) * 1985-07-05 1987-12-08 Sclavo S.P.A. Glycoproteinic conjugates having trivalent immunogenic activity
US6372222B1 (en) * 1995-06-07 2002-04-16 Baxter International Inc. Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
WO2000010599A2 (fr) * 1998-08-19 2000-03-02 North American Vaccine, Inc. Conjugue de proteine-polysaccharide immunogene a liaison beta-propionamido, utile comme vaccin etabli au moyen d'un polysaccharide n-acryloyle

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DROGARI-APIRANTHITOU M ET AL: "Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 119, no. 2, February 2000 (2000-02-01), pages 311 - 316, XP002263579, ISSN: 0009-9104 *
FUSCO P C ET AL: "MENINGOCOCCAL VACCINE DEVELOPMENT: A NOVEL APPROACH", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 7, no. 2, 1998, pages 245 - 252, XP000872557, ISSN: 1354-3784 *
PAOLETTI L C ET AL: "NEONATAL MOUSE PROTECTION AGAINST INFECTION WITH MULTIPLE GROUP B STREPTOCOCCAL (GBS) SEROTYPES BY MATERNAL IMMUNIZATION WITH A TETRAVALENT GBS POLYSACCHARIDE-TETANUS TOXOID CONJUGATE VACCINE", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 62, no. 8, August 1994 (1994-08-01), pages 3236 - 3243, XP001148813, ISSN: 0019-9567 *

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7972608B2 (en) * 2003-06-23 2011-07-05 Baxter International Inc. Carrier proteins for vaccines
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
US10064932B2 (en) 2004-04-30 2018-09-04 Glaxosmithkline Biologicals S.A. Integration of meningococcal conjugate vaccination
AU2005302269B2 (en) * 2004-11-01 2011-05-19 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
JP2008518953A (ja) * 2004-11-01 2008-06-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 連鎖球菌修飾多糖類およびそれらの使用法
EP1812057A4 (fr) * 2004-11-01 2009-07-22 Brigham & Womens Hospital Polysaccharides streptococciques modifies et leurs utilisations
US7858101B2 (en) 2004-11-01 2010-12-28 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
US8529908B2 (en) 2005-01-14 2013-09-10 Novartis Ag Meningococcal conjugate vaccination
AU2006211052B2 (en) * 2005-02-01 2012-03-29 Novartis Vaccines And Diagnostics Srl Conjugation of streptococcal capsular saccharides
CN101304765B (zh) * 2005-02-01 2013-03-27 诺华疫苗和诊断有限公司 链球菌荚膜糖的偶联
EP2270056A2 (fr) 2005-02-01 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Purification du polysaccharide capsulaire de streptococcus
WO2006082530A3 (fr) * 2005-02-01 2008-07-03 Novartis Vaccines & Diagnostic Conjugaison de saccharides capsulaires streptococciques
US9040055B2 (en) 2005-02-01 2015-05-26 Novartis Vaccines And Diagnostics Srl Conjugation of streptococcal capsular saccharides
US9675691B2 (en) 2005-02-01 2017-06-13 Glaxosmithkline Biologicals Sa Conjugation of streptococcal capsular saccharides
JP2008532930A (ja) * 2005-02-01 2008-08-21 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 連鎖球菌性莢膜糖の複合
US20130295132A1 (en) * 2005-02-01 2013-11-07 Novartis Vaccines And Diagnostics Srl Conjugation of Streptococcal Capsular Saccharides
CN103349780A (zh) * 2005-02-01 2013-10-16 诺华疫苗和诊断有限公司 链球菌荚膜糖的偶联
US10188719B2 (en) 2005-02-01 2019-01-29 Glaxosmithkline Biologicals S.A. Conjugation of Streptococcal capsular saccharides
US8513392B2 (en) 2005-02-01 2013-08-20 Novartis Vaccines And Diagnostics Srl Conjugation of streptococcal capsular saccharides
EP3498302A1 (fr) 2005-02-01 2019-06-19 Novartis Vaccines and Diagnostics S.r.l. Conjugaison de saccharides capsulaires streptococciques
EP2425855A1 (fr) * 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
EP2425856A1 (fr) * 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
US10716848B2 (en) 2005-04-08 2020-07-21 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
US9399060B2 (en) 2005-04-08 2016-07-26 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2006110381A1 (fr) 2005-04-08 2006-10-19 Wyeth Composition conjuguee polysaccharide-proteine pneumococcique polyvalente
US11191830B2 (en) 2005-04-08 2021-12-07 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
EP2425854A1 (fr) * 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP4005595A1 (fr) * 2005-04-08 2022-06-01 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
EP2425851A1 (fr) * 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
EP2425852A1 (fr) * 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
US10780160B2 (en) 2005-04-08 2020-09-22 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
US8603484B2 (en) 2005-04-08 2013-12-10 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9981045B2 (en) 2005-04-08 2018-05-29 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9981035B2 (en) 2005-04-08 2018-05-29 Wyeth Llc Process for preparing pneumococcal polysaccharide-protein conjugates
US8808708B2 (en) 2005-04-08 2014-08-19 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3311836A1 (fr) * 2005-04-08 2018-04-25 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
US8895024B2 (en) 2005-04-08 2014-11-25 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8895724B2 (en) 2005-04-08 2014-11-25 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (fr) * 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
US11969474B2 (en) 2005-04-08 2024-04-30 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9480736B2 (en) 2005-04-08 2016-11-01 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8431136B2 (en) 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9358279B2 (en) 2005-06-27 2016-06-07 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP3009146A1 (fr) * 2005-06-27 2016-04-20 GlaxoSmithKline Biologicals S.A. Composition immunogène
US10245317B2 (en) 2005-06-27 2019-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8883163B2 (en) 2005-06-27 2014-11-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2878307A1 (fr) * 2005-06-27 2015-06-03 GlaxoSmithKline Biologicals S.A. Composition immunogène
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
US10166287B2 (en) 2005-06-27 2019-01-01 Glaxosmithkline Biologicals S.A. Immunogenic composition
US11241495B2 (en) 2005-06-27 2022-02-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
US10279033B2 (en) 2005-12-22 2019-05-07 Glaxosmithkline Biologicals Sa Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
US10646564B2 (en) 2005-12-22 2020-05-12 Glaxosmithkline Biologicals S.A. Vaccine
US9884113B2 (en) 2005-12-22 2018-02-06 Glaxosmithkline Biologicals, Sa Pneumoccal polysacchride conjugate vaccine
US9107872B2 (en) 2005-12-22 2015-08-18 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
US11400147B2 (en) 2005-12-22 2022-08-02 Glaxosmithkline Biologicals Sa Pneumococcal capsular saccharide conjugate vaccine
EP2891498A1 (fr) 2007-12-20 2015-07-08 Novartis AG Procédés de fermentation pour cultiver des streptocoques et procédés de purification pour obtenir des CPS à partir de ceux-ci
WO2010049806A1 (fr) 2008-10-27 2010-05-06 Novartis Ag Procédé de purification
EP3199177A1 (fr) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
WO2011051917A1 (fr) 2009-10-30 2011-05-05 Novartis Ag Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
JP2013538228A (ja) * 2010-09-16 2013-10-10 ノバルティス アーゲー 免疫原性組成物
WO2012035519A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Compositions immunogènes
WO2013009564A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Procédé de ligature de la tyrosine
WO2013068949A1 (fr) 2011-11-07 2013-05-16 Novartis Ag Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
WO2013174832A1 (fr) 2012-05-22 2013-11-28 Novartis Ag Conjugué de sérogroupe x de méningocoque
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
US10286055B2 (en) 2012-10-03 2019-05-14 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3482770A1 (fr) 2012-10-03 2019-05-15 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
WO2014053612A1 (fr) 2012-10-03 2014-04-10 Novartis Ag Composition immunogène
WO2014053607A1 (fr) 2012-10-03 2014-04-10 Novartis Ag Compositions immunogènes
CN104174019A (zh) * 2014-09-23 2014-12-03 成都康华生物制品有限公司 四价脑膜炎球菌多糖载体蛋白结合疫苗
WO2016097147A1 (fr) 2014-12-19 2016-06-23 Glaxosmithkline Biologicals Sa Purification de polysaccharides capsulaire streptococciques
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
US10226525B2 (en) * 2015-05-04 2019-03-12 Pfizer Inc. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US20160324950A1 (en) * 2015-05-04 2016-11-10 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US10946086B2 (en) 2015-05-04 2021-03-16 Pfizer Inc. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN107847578A (zh) * 2015-07-01 2018-03-27 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2017001586A1 (fr) * 2015-07-01 2017-01-05 Glaxosmithkline Biologicals S.A. Compositions immunogènes
BE1024282B1 (fr) * 2015-07-01 2018-01-15 Glaxosmithkline Biologicals Sa Compositions immunogènes
JP2018087181A (ja) * 2016-11-09 2018-06-07 ファイザー・インク 免疫原性組成物およびその使用
WO2018087635A1 (fr) * 2016-11-09 2018-05-17 Pfizer Inc. Protéine et polysaccharide immunogènes conjugués comprenant un polysaccharide dérivé du streptococcus gbs
KR20190064616A (ko) * 2016-11-09 2019-06-10 화이자 인코포레이티드 B 스트렙토코쿠스 gbs로부터 유래된 폴리사카라이드를 포함하는 면역원성 폴리사카라이드 단백질 접합체
CN110049776A (zh) * 2016-11-09 2019-07-23 辉瑞大药厂 包含衍生自b族链球菌gbs的多糖的缀合蛋白质的免疫原性多糖
JP2022024175A (ja) * 2016-11-09 2022-02-08 ファイザー・インク 免疫原性組成物およびその使用
US12527855B2 (en) 2016-11-09 2026-01-20 Pfizer Inc. Immunogenic compositions and uses thereof
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11147865B2 (en) 2016-11-09 2021-10-19 Pfizer Inc. Immunogenic compositions and uses thereof
RU2791468C2 (ru) * 2016-11-09 2023-03-09 Пфайзер Инк. Иммуногенные полисахарид-белковые коньюгаты, содержащие полисахарид, полученный из стрептококка группы b (gbs)
JP7295206B2 (ja) 2016-11-09 2023-06-20 ファイザー・インク 免疫原性組成物およびその使用
KR102554777B1 (ko) 2016-11-09 2023-07-11 화이자 인코포레이티드 B 스트렙토코쿠스 gbs로부터 유래된 폴리사카라이드를 포함하는 면역원성 폴리사카라이드 단백질 접합체
CN110049776B (zh) * 2016-11-09 2023-09-08 辉瑞大药厂 包含衍生自b族链球菌gbs的多糖的缀合蛋白质的免疫原性多糖
AU2017357679B2 (en) * 2016-11-09 2024-09-26 Pfizer Inc. Immunogenic polysaccharide protein conjugated comprising a polysaccharide derived from B streptococcus GBS
US12016913B2 (en) 2016-11-09 2024-06-25 Pfizer Inc. Immunogenic compositions and uses thereof
WO2018104889A1 (fr) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Procédé de purification pour polysaccharide capsulaire
WO2022043855A1 (fr) * 2020-08-26 2022-03-03 Pfizer Inc. Conjugués polysaccharide-protéine de streptococcus du groupe b, procédés de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations

Also Published As

Publication number Publication date
US20040096461A1 (en) 2004-05-20
AU2003257003A1 (en) 2004-02-16
US20150093411A1 (en) 2015-04-02
AU2003257003A8 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
US20150093411A1 (en) Chimeric Multivalent Polysaccharide Conjugate Vaccines
US6329512B1 (en) Immunogenic conjugate molecules
EP2170391B1 (fr) Polysaccharides modifiés pour vaccins conjugués
US6656472B1 (en) Multi oligosaccharide glycoconjugate bacterial meningitis vaccines
WO2012082635A1 (fr) Streptocoque du groupe a à base d'oligosaccharides synthétiques
JP2004505885A (ja) Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
US20240366743A1 (en) Multivalent Pneumococcal Glycoconjugate Vaccines Containing Emerging Serotype 24F
AU2005302269B2 (en) Modified streptococcal polysaccharides and uses thereof
EP0831894A1 (fr) Compositions oligasaccharidiques immunogenes et immunostimulatrices et leurs procedes de production et d'utilisations
JP2005508854A (ja) 低分子量ヒアルロン酸とポリペプチド毒素との免疫原性結合体
US20160375120A1 (en) Synthetic oligosaccharides for moraxella vaccine
AU779038B2 (en) IGA1 protease fragment as carrier peptide
MXPA00008255A (en) Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP